New yew alcohol preparations! Oasmia's Apealea (Yew alcohol beam) has been approved by the European Union to treat relapsed eggs:

Oasmia is a Swedish biopharmaceutical company focused on innovative treatments for human and animal tumors. Recently, the company announced that the European Commission (EC) has approved the treatment of Apealea (paclitaxel micellar, yew alcohol beam), a joint carp platinum for the first recurrence of platinum-sensitive epithelyl ovarian cancer, primary peritina cancer, fallopian tube cancer in adult patients. The ratification applies to 28 EU member states and EEA countries Iceland, Liechtenstein and Norway.
approval marks the first systematic combination therapy for platinum-sensitive endoskine cancer to be approved in Europe for the first recurrence of platinum-sensitive endoskine cancer. This is an important milestone for the group of patients in Europe who are experiencing a recurrence of ovarian cancer, as Apealea allows the use of high doses of polyoxyethylene castor oil (CrEL) in combination with platinum chemotherapy.
is one of the most widely used anti-cancer drugs and has been widely used in standard treatment options for a wide range of cancers, including breast, lung and ovarian cancer. Yew alcohol anti-cancer effect is good, but there are defects, the biggest problem is that yew alcohol is insoluble in water, so the need to use special solvents, but these solvents themselves can cause trouble. For example, dissolved yew alcohol is commonly used in polyoxyethylene castor oil (CrEL), a solvent itself that causes severe allergic reactions in the body and directly limits clinical use.
Apealea is a polyoxyethylene castor oil (CrEL) and albumin-free yew alcohol preparation, composed of freeze-dried powder, dissolved in conventional solutions for infusion, very convenient to use.
apealea combines Oasismia's proprietary shaper XR17. XR17 is a vitamin A-based substance that forms a 20-60 nanometer-sized beam. XR17 is also unique in that it can also form a glue beam with a water-soluble substance. This greatly increases the potential use of the XR17. Once XR17 delivers one or more of the ensealed molecules to the target, the emoticon is metabolized naturally. More recently, new patents related to Oasmia's XR17 nanotechnology platform have been approved by the U.S. Patent and Trademark Office (USPTO).
Apealea's approval is based on data from a number of clinical studies, including a key study in patients with relapsed disease, OAS 07OVA, from which data from the apealea-carptin combination therapy had a similar risk of disease progress or death compared to the combination therapy of yew alcohol-carplatin made with polyoxyethylene castor oil (CrEL). The specific data are, no progress lifetime (medium PFS: 10.3 months vs 10.1 months, HR=0.86,95% CI:0.72-1.0) 3); Total lifetime (medium OS: 25.7 months vs 24.8 months, HR:0.95, 95% CI:0.78-1.16). (Bio Valley)